^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    FOLH1 expression

    i
    Other names: FOLH1, FOLH, GCP2, GCPII, NAALAD1, NAALAdase, PSM, PSMA, Folate hydrolase 1, prostate-specific membrane antigen
    Entrez ID:
    2346
    Related biomarkers:
    Expression
    Apply
    Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer (NCT04573231)
    Phase 2
    University of Wisconsin, Madison
    Recruiting
    Last update posted :
    05/22/2024
    Initiation :
    05/24/2021
    Primary completion :
    11/01/2025
    Completion :
    11/01/2025
    HER-2 • FOLH1
    |
    HER-2 negative • AR expression • FOLH1 expression
    ARX517 in Subjects With Metastatic Castration-Resistant Prostate Cancer (APEX-01) (NCT04662580)
    Phase 1
    Ambrx, Inc.
    Recruiting
    Last update posted :
    05/10/2024
    Initiation :
    07/27/2021
    Primary completion :
    12/01/2025
    Completion :
    03/01/2027
    FOLH1
    |
    FOLH1 expression
    |
    Xtandi (enzalutamide) • JNJ-95298177
    CART-PSMA-TGFβRDN Cells for Castrate-Resistant Prostate Cancer (NCT03089203)
    Phase 1
    University of Pennsylvania
    Active, not recruiting
    Last update posted :
    04/26/2024
    Initiation :
    03/08/2017
    Primary completion :
    09/08/2038
    Completion :
    12/08/2038
    TGFB1
    |
    FOLH1 expression
    |
    cyclophosphamide • fludarabine IV • CART-PSMA- TGFβRDN cells
    PSMA PET/MRI or PSMA PET/CT for Evaluation of Liver Cancer (NCT04310540)
    Phase 1
    Mayo Clinic
    Completed
    Last update posted :
    04/11/2024
    Initiation :
    06/05/2020
    Primary completion :
    11/02/2023
    Completion :
    11/02/2023
    FOLH1
    |
    FOLH1 expression
    NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial (NCT06066437)
    Phase 1/2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    04/01/2024
    Initiation :
    03/29/2024
    Primary completion :
    06/30/2025
    Completion :
    06/30/2026
    FOLH1
    |
    FOLH1 expression
    |
    Firmagon (degarelix)
    A Trial to Find Out if REGN5678 is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors (NCT03972657)
    Phase 1/2
    Regeneron Pharmaceuticals
    Recruiting
    Last update posted :
    03/08/2024
    Initiation :
    08/12/2019
    Primary completion :
    08/01/2025
    Completion :
    07/03/2026
    FOLH1
    |
    FOLH1 expression
    |
    Libtayo (cemiplimab-rwlc) • Kevzara (sarilumab) • nezastomig (REGN5678)
    Role of F-18 PSMA in Prostate Cancer Patient (NCT06209853)
    Phase N/A
    Assiut University
    Not yet recruiting
    Last update posted :
    01/18/2024
    Initiation :
    01/15/2024
    Primary completion :
    03/01/2025
    Completion :
    04/01/2025
    FOLH1
    |
    FOLH1 expression
    68Ga-PSMA-Dual-Contrast PET/MRI or PET/CT for Early Detection of Liver Cancer (NCT04762888)
    Phase 2
    Mayo Clinic
    Recruiting
    Last update posted :
    01/18/2024
    Initiation :
    02/24/2021
    Primary completion :
    01/10/2025
    Completion :
    07/07/2025
    FOLH1
    |
    FOLH1 expression • FOLH1 overexpression
    A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy (PRODIGY-1) (NCT05896371)
    Phase 1/2
    CHU de Quebec-Universite Laval
    Not yet recruiting
    Last update posted :
    11/22/2023
    Initiation :
    01/29/2024
    Primary completion :
    06/15/2028
    Completion :
    06/15/2032
    FOLH1
    |
    FOLH1 expression
    CART-PSMA Cells for Advanced Prostate Cancer (NCT05656573)
    Phase 1
    Nova Therapeutics LLC
    Recruiting
    Last update posted :
    11/08/2023
    Initiation :
    03/01/2023
    Primary completion :
    12/01/2024
    Completion :
    12/01/2025
    IFNG • IL6 • TNFA • IL2 • IL10
    |
    FOLH1 expression
    |
    cyclophosphamide • CART-PSMA
    177Lu-P17-087/177Lu-P17-088 in Patients With Metastatic Castration-resistant Prostate Cancer (NCT05603559)
    Phase 1
    Peking Union Medical College Hospital
    Completed
    Last update posted :
    10/23/2023
    Initiation :
    01/01/2023
    Primary completion :
    09/05/2023
    Completion :
    10/04/2023
    FOLH1
    |
    FOLH1 expression • FOLH1 overexpression
    |
    177Lu-P17-087 • 177Lu-P17-088
    Tracer-Guided Surgery for Recurrent Prostate Cancer (Trace-II) (NCT05555017)
    Phase 2
    The Netherlands Cancer Institute
    Recruiting
    Last update posted :
    10/06/2023
    Initiation :
    02/15/2023
    Primary completion :
    11/01/2024
    Completion :
    11/01/2025
    FOLH1
    |
    FOLH1 expression
    |
    triptorelin
    PSMA Expression and PSMA PET Imaging in Soft Tissue Sarcomas and Urothelial Cell Carcinomas (NL78279.058.21) (NCT05522257)
    Phase N/A
    Leiden University Medical Center
    Recruiting
    Last update posted :
    09/29/2023
    Initiation :
    08/01/2022
    Primary completion :
    05/01/2024
    Completion :
    06/01/2024
    FOLH1
    |
    FOLH1 expression
    PSMA-PET/CT to Assess the Expression of Specific Membrane Antigen (PSMA) in Patients With Progressive Triple-negative Breast Cancer. (PRISMA) (NCT06059469)
    Phase 2
    Jules Bordet Institute
    Recruiting
    Last update posted :
    09/28/2023
    Initiation :
    05/30/2022
    Primary completion :
    06/01/2024
    Completion :
    09/01/2024
    FOLH1
    |
    FOLH1 expression
    Copper-64 SAR Bombesin in PSMA Negative Prostate Cancer (BOP) (NCT05613842)
    Phase 2
    St Vincent's Hospital, Sydney
    Completed
    Last update posted :
    09/26/2023
    Initiation :
    08/09/2022
    Primary completion :
    06/06/2023
    Completion :
    06/06/2023
    FOLH1
    |
    FOLH1 expression
    PSMA in Gastrointestinal Tumors (GIPSMA, Focusing on Neuroendocrine Neoplasms) (NCT05547919)
    Phase N/A
    Wuerzburg University Hospital
    Recruiting
    Last update posted :
    09/13/2023
    Initiation :
    10/01/2022
    Primary completion :
    10/01/2024
    Completion :
    10/01/2026
    FOLH1
    |
    FOLH1 expression
    ACTInium-J591 Radionuclide Therapy in PSMA-Detected Metastatic HOrmone-Sensitive Recurrent Prostate CaNcer (ACTION) (NCT05567770)
    Phase 1
    Weill Medical College of Cornell University
    Withdrawn
    Last update posted :
    08/24/2023
    Initiation :
    12/01/2023
    Primary completion :
    01/01/2025
    Completion :
    01/01/2030
    FOLH1
    |
    FOLH1 expression
    |
    Ac-225 rosopatamab tetraxetan (CONV01-α)
    Use of 18F-PSMA-11 PET for Detection of Lesions in Iodine Refractory Thyroid Cancers (NCT05175404)
    Phase 2
    University Hospital, Ghent
    Completed
    Last update posted :
    08/24/2023
    Initiation :
    01/24/2022
    Primary completion :
    07/18/2023
    Completion :
    07/18/2023
    TG
    |
    FOLH1 expression
    68Ga-P3 PET/CT Imaging in Malignancy (NCT05887687)
    Phase N/A
    Peking University First Hospital
    Recruiting
    Last update posted :
    06/06/2023
    Initiation :
    05/20/2023
    Primary completion :
    07/31/2025
    Completion :
    07/31/2025
    FOLH1
    |
    FOLH1 expression
    Clinical Application of 68Ga-PSMA PET/MR for Diagnosis and Staging in Hepatocellular Carcinoma (NCT05006326)
    Phase N/A
    Wuhan Union Hospital, China
    Recruiting
    Last update posted :
    02/14/2023
    Initiation :
    08/16/2021
    Primary completion :
    12/31/2023
    Completion :
    12/31/2023
    AFP • FOLH1
    |
    FOLH1 expression
    Prospective REgistry of Targeted RadionucLide TherapY in Patients With mCRPC (REALITY Study) (NCT04833517)
    Phase N/A
    Universität des Saarlandes
    Recruiting
    Last update posted :
    12/08/2022
    Initiation :
    01/01/2016
    Primary completion :
    12/31/2024
    Completion :
    12/31/2025
    FOLH1
    |
    FOLH1 expression
    68Ga-P15-041 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Prostate Bone Metastasis (NCT05627778)
    Phase 1/2
    Peking Union Medical College Hospital
    Recruiting
    Last update posted :
    11/28/2022
    Initiation :
    11/01/2021
    Primary completion :
    12/01/2022
    Completion :
    12/01/2022
    FOLH1
    |
    FOLH1 expression
    177Lu-PSMA-EB-01 in Patients With Metastatic Castration-resistant Prostate Cancer (NCT05613738)
    Phase N/A
    Peking Union Medical College Hospital
    Recruiting
    Last update posted :
    11/11/2022
    Initiation :
    11/23/2022
    Primary completion :
    06/30/2023
    Completion :
    11/15/2023
    FOLH1
    |
    FOLH1 expression • FOLH1 overexpression
    |
    177Lu-LNC1003
    Radio-guided Surgery With DROP-IN Beta Probe for 68Ga-PSMA, in High-risk Prostate Cancer Patients Eligible for Robotic-assisted Radical Prostatectomy. (NCT05596851)
    Phase N/A
    European Institute of Oncology
    Recruiting
    Last update posted :
    10/27/2022
    Initiation :
    03/21/2022
    Primary completion :
    09/01/2023
    Completion :
    12/01/2023
    FOLH1
    |
    FOLH1 expression • FOLH1 positive
    68Ga-PSMA PET in Diagnosing Metastasis in Patients With Ovarian Cancer (NCT03857087)
    Phase N/A
    University of California, San Francisco
    Completed
    Last update posted :
    10/12/2022
    Initiation :
    04/02/2018
    Primary completion :
    06/30/2022
    Completion :
    06/30/2022
    FOLH1
    |
    FOLH1 expression
    PSMA-PET Imaging Before and After ADT in Advanced SDC Patients (ADT-SCAN) (NCT04214353)
    Phase N/A
    Radboud University Medical Center
    Recruiting
    Last update posted :
    08/16/2022
    Initiation :
    01/14/2020
    Primary completion :
    05/01/2023
    Completion :
    09/01/2023
    AR • FOLH1
    |
    AR positive • FOLH1 expression
    Study of Anti-PSMA CAR NK Cell (TABP EIC) in Metastatic Castration-Resistant Prostate Cancer (NCT03692663)
    Phase 1
    Allife Medical Science and Technology Co., Ltd.
    Recruiting
    Last update posted :
    08/01/2022
    Initiation :
    12/01/2018
    Primary completion :
    06/01/2023
    Completion :
    06/01/2024
    NCAM1
    |
    FOLH1 expression
    |
    cyclophosphamide • fludarabine IV • ALF501
    Therapeutic Efficiency and Response to 2.0 GBq (55mCi) 177Lu-EB-PSMA in Patients With mCRPC (NCT04996602)
    Phase 1
    Peking Union Medical College Hospital
    Recruiting
    Last update posted :
    07/15/2022
    Initiation :
    01/14/2019
    Primary completion :
    09/01/2022
    Completion :
    12/01/2022
    FOLH1
    |
    FOLH1 expression • FOLH1 overexpression
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    Lu177-EB-PSMA617 Radionuclide Treatment in Patients With Metastatic Castration-resistant Prostate Cancer (NCT03780075)
    Phase 1
    Peking Union Medical College Hospital
    Recruiting
    Last update posted :
    05/12/2022
    Initiation :
    04/15/2018
    Primary completion :
    09/01/2020
    Completion :
    12/01/2022
    FOLH1
    |
    FOLH1 expression • FOLH1 overexpression
    Neoadjuvant Degarelix With or Without Apalutamide (ARN-509) Followed by Radical Prostatectomy (ARNEO) (NCT03080116)
    Phase 2
    Universitaire Ziekenhuizen Leuven
    Recruiting
    Last update posted :
    12/24/2020
    Initiation :
    03/28/2019
    Primary completion :
    06/30/2021
    Completion :
    12/30/2021
    PTEN • FOLH1 • SPOP
    |
    FOLH1 expression
    |
    Erleada (apalutamide) • Firmagon (degarelix)
    Feasibility Study of 68Ga-PSMA PET-CT and 18F-FDOPA PET-CT in Glioblastoma's Patients (PAraDiGM) (NCT03903419)
    Phase N/A
    Centre Leon Berard
    Recruiting
    Last update posted :
    10/14/2020
    Initiation :
    01/16/2019
    Primary completion :
    08/16/2021
    Completion :
    08/16/2021
    FOLH1
    |
    FOLH1 expression
    Neoadjuvant J591 Treatment for Prostate Cancer (NCT02693860)
    Phase 1
    Weill Medical College of Cornell University
    Completed
    Last update posted :
    10/05/2020
    Initiation :
    02/04/2016
    Primary completion :
    02/10/2017
    Completion :
    02/02/2020
    FOLH1
    |
    FOLH1 expression
    Technetium Based Radioguided Surgery for Prostate Cancer (TRACE) Study (NCT03857113)
    Phase N/A
    The Netherlands Cancer Institute
    Unknown status
    Last update posted :
    07/22/2020
    Initiation :
    03/11/2020
    Primary completion :
    03/01/2022
    Completion :
    03/01/2022
    FOLH1
    |
    FOLH1 expression
    177Lu-PSMA-I&T Prior to Radical Prostatectomy for Locally Advanced Disease (NALuPROST) (NCT04297410)
    Phase N/A
    Rabin Medical Center
    Unknown status
    Last update posted :
    03/05/2020
    Initiation :
    11/20/2019
    Primary completion :
    11/20/2021
    Completion :
    04/20/2022
    FOLH1
    |
    FOLH1 expression • FOLH1 overexpression
    Comparison of PET With [89Zr]-Df-IAb2M and [111In]-Capromab Pendetide in the Detection of Prostate Cancer Pre-Prostatectomy (NCT02349022)
    Phase 2
    ImaginAb, Inc.
    Completed
    Last update posted :
    02/13/2020
    Initiation :
    01/01/2015
    Primary completion :
    04/01/2016
    Completion :
    07/01/2016
    FOLH1
    |
    B2M elevation • FOLH1 expression
    |
    177Lu-capromab pendetide (CYT 500)
    Pilot Study of 18F-DCFPyL PET/CT in the Evaluation of Men With an Elevated PSA Following Radical Prostatectomy (NCT02523924)
    Phase N/A
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Completed
    Last update posted :
    01/31/2020
    Initiation :
    06/02/2015
    Primary completion :
    11/04/2016
    Completion :
    03/04/2019
    FOLH1
    |
    FOLH1 expression
    177Lu-EB-PSMA617 in Patients With Metastatic Castration-resistant Prostate Cancer (NCT03403595)
    Phase 1
    Peking Union Medical College Hospital
    Unknown status
    Last update posted :
    01/18/2018
    Initiation :
    12/01/2017
    Primary completion :
    12/01/2018
    Completion :
    12/01/2018
    FOLH1
    |
    FOLH1 expression • FOLH1 overexpression
    Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA (NCT02607553)
    Phase 2
    GenSpera, Inc.
    Completed
    Last update posted :
    02/24/2017
    Initiation :
    06/01/2016
    Primary completion :
    12/01/2016
    Completion :
    02/01/2017
    FOLH1
    |
    FOLH1 expression
    |
    mipsagargin (G-202)
    Pilot Study of 99mTc-MIP-1404 SPECT/CT Imaging in Men With Prostate Cancer Undergoing Prostatectomy and/or Pelvic Lymph Node Dissection (NCT01572701)
    Phase 1
    Molecular Insight Pharmaceuticals, Inc.
    Completed
    Last update posted :
    11/25/2015
    Initiation :
    01/01/2012
    Primary completion :
    06/01/2012
    FOLH1
    |
    FOLH1 expression